<DOC>
	<DOCNO>NCT01536561</DOCNO>
	<brief_summary>Phase I/II , single-center , dose-escalation study safety , pharmacokinetics , dosimetry , efficacy TST/I-131 TST treatment patient chemotherapy-refractory resistant low-grade , intermediate-grade , high-grade B-cell lymphoma . Subjects receive 1 3 dosimetric dos follow therapeutic dose TST/I-131 TST . Study BEX104526 follow-up study long-term safety efficacy data survive patient complete least 2 year follow-up follow administration TST/I 131 TST Study BEX104728 . Dosimetric dose : Subjects receive 1 3 dosimetric dos TST/I-131 TST , follow therapeutic dose TST/I-131 TST . Subjects receive various dos unlabeled TST ( 0 , 95 475 mg ) determine dose unlabeled TST optimize radiation dose deliver tumor TST/I-131 TST . The unlabeled TST follow 5 milliCurie ( mCi ) I-131 TST . Serial whole body sodium iodide scintillation probe count obtain daily , least 5 day , order determine rate whole body clearance radioactivity ( residence time ) . The residence time use determine radioactive clearance subject activity ( mCi ) I-131 require deliver desire TBD radiation therapeutic dose . Because 475 mg determine optimal pre-dose TST first subject enter , last 34 subject receive single dosimetric dose precede infusion 475 mg TST . Therapeutic dose : Groups 3-6 subject enrol successively high whole-body radiation dose level begin total body dose ( TBD ) 25 centiGray ( cGy ) . The TBD subsequent dose level escalate 10 cGy . Subjects undergone bone marrow transplantation ( BMT ) underwent separate dose escalation ( 10 cGy TBD increase per dose level ) begin TBD level 65 cGy . The MTD define high dose level 0/3 1/6 subject experience dose-limiting toxicity ( DLT ) . DLT define follow : Any Grade 4 hematologic toxicity ( National Cancer Institute [ NCI ] criterion ) last great 7 day , Any Grade 3 hematologic toxicity last great 2 week , Any Grade 3 4 nonhematologic toxicity Redosing . Subjects achieve tumor regression consider re-dosing , use original therapeutic dose TST/I-131 TST , time tumor longer shrink attempt upgrade response . Retreatment . Subjects achieve partial ( PR ) complete response ( CR ) consider retreatment follow relapse NHL , progression occur ≥6 week follow therapeutic dose . The original therapeutic dose TST/I-131 TST give unless grade 2 great toxicity encounter , case reduce dose administer repeat therapeutic dose .</brief_summary>
	<brief_title>Study Radiolabeled Monoclonal Antibody Anti-B1 Treatment B-Cell Lymphomas Extended Study Determine Safety Efficacy Coulter Clone® 131Iodine-B1 Radioimmunotherapy Advanced Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Phase I/II , single-center , dose-escalation study safety , pharmacokinetics , dosimetry , efficacy TST/I-131 TST treatment patient chemotherapy-refractory resistant low-grade , intermediate-grade , high-grade B-cell lymphoma . Subjects receive 1 3 dosimetric dos follow therapeutic dose TST/I-131 TST . Study BEX104526 follow-up study long-term safety efficacy data survive patient complete least 2 year follow-up follow administration TST/I 131 TST Study BEX104728 . Dosimetric dose : Subjects receive 1 3 dosimetric dos TST/I-131 TST , follow therapeutic dose TST/I-131 TST . Subjects receive various dos unlabeled TST ( 0 , 95 475 mg ) determine dose unlabeled TST optimize radiation dose deliver tumor TST/I-131 TST . The unlabeled TST follow 5 milliCurie ( mCi ) I-131 TST . Serial whole body sodium iodide scintillation probe count obtain daily , least 5 day , order determine rate whole body clearance radioactivity ( residence time ) . The residence time use determine radioactive clearance subject activity ( mCi ) I-131 require deliver desire TBD radiation therapeutic dose . Because 475 mg determine optimal pre-dose TST first subject enter , last 34 subject receive single dosimetric dose precede infusion 475 mg TST . Therapeutic dose : Groups 3-6 subject enrol successively high whole-body radiation dose level begin total body dose ( TBD ) 25 centiGray ( cGy ) . The TBD subsequent dose level escalate 10 cGy . Subjects undergone bone marrow transplantation ( BMT ) underwent separate dose escalation ( 10 cGy TBD increase per dose level ) begin TBD level 65 cGy . The MTD define high dose level 0/3 1/6 subject experience dose-limiting toxicity ( DLT ) . DLT define follow : Any Grade 4 hematologic toxicity ( National Cancer Institute [ NCI ] criterion ) last great 7 day , Any Grade 3 hematologic toxicity last great 2 week , Any Grade 3 4 nonhematologic toxicity Redosing : Subjects achieve tumor regression consider re-dosing , use original therapeutic dose TST/I-131 TST , time tumor longer shrink attempt upgrade response . Retreatment : Subjects achieve partial response ( PR ) complete response ( CR ) consider retreatment follow relapse NHL , progression occur ≥6 week follow therapeutic dose . The original therapeutic dose TST/I-131 TST give unless grade 2 great toxicity encounter , case reduce dose administer repeat therapeutic dose . Subjects complete least 2 year follow-up BEX104728 enrol LTFU Study BEX104526 continue radiographic response evaluation safety evaluation every 6 month year 3 5 post-treatment annually year 6 10 post-treatment . Subjects BEX104526 assess survival disease status , include subsequent therapy NHL , long-term safety , include development hypothyroidism , myelodysplastic syndrome ( MDS ) , acute myelogenous leukemia ( AML ) , secondary malignancy . Additionally , subject follow development adverse event ( ) ( AEs ) deem Principal Investigator possibly probably related subject 's treatment TST/I-131 TST . Laboratory evaluation , consist thyroid stimulate hormone ( TSH ) level complete blood cell count differential platelet count , obtain annually year 10 post-treatment . Study assessment include demographic baseline characteristic ; tumor response , duration response , survival ( progression-free survival [ PFS ] overall survival [ OS ] ) , adverse event ( AEs ) , incidence human anti-murine antibody ( HAMA ) , incidence hypothyroidism , serious ( fatal non-fatal ) adverse event ( SAEs ) . Dosing ; '' Dosimetric Doses '' , Intravenous ( IV ) administration unlabeled TST ( 0 , 95 475 mg ) administer determine dose unlabeled TST optimize radiation dose tumor . This follow 5 mCi I-131 TST . Serial whole body sodium iodide scintillation probe count obtain daily , least 5 day , order determine rate whole body clearance radioactivity ( residence time ) . The residence time use determine radioactive clearance subject subsequently activity ( mCi ) Iodine-131 require deliver desire TBD radiation therapeutic dose TST/I-131 TST . Because 475 mg determine optimal pre-dose tositumomab first subject enter , last 34 subject receive single dosimetric dose precede infusion 475 mg tositumomab ( Source Data : Listing 13 ) . `` Therapeutic Dose '' , Groups 3-6 subject treat successively higher therapeutic whole body radiation dos , begin TBD 25 cGy . The TBD escalate 10 cGy increment subsequent dose level cohort MTD achieve . A separate determination MTD conduct subject undergone prior BMT . This initiated TBD 65 cGy TBD increase 10 cGy increment determination MTD . The MTD define dose few 1/3 2/6 subject experienced DLT , i.e . Grade 4 hematologic toxicity ( absolute neutrophil count [ ANC ] , platelet , hemoglobin , white blood count [ WBC ] last &gt; 7 day Grade 3 hematologic toxicity last &gt; 14 day , define Section 4.1 . Re-Dosing ; Subjects achieve tumor regression consider re-dosing , use original therapeutic dose TST/I-131 TST , time tumor longer shrink attempt upgrade response . Patients redo sooner 6 week follow therapeutic dose . Retreatment ( ≥6 week follow therapeutic dose ) ; Subjects achieve PR CR consider retreatment follow relapse NHL . The original therapeutic dose TST/I-131 TST give unless Grade 2 great toxicity encounter , case dose level immediately original dose administer .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antibodies , Anti-Idiotypic</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Inclusion Criteria Subjects histologicallyconfirmed NHL . Subjects low , intermediate , highgrade histology , accord International Working Formulation . Subjects relapse failed respond least 1 prior chemotherapy regimen . Subjects evidence tumor tissue express CD20 antigen . Exclusion Criteria ≥25 % bone marrow involvement . Absolute granulocyte count ≥1500 cells/mm3 platelet count ≤100,000 platelets/mm3 . Creatinine ≥2.0 mg/dL , bilirubin ≥2.0 mg/dL . Cytotoxic chemotherapy , radiation therapy , immunosuppressant , cytokine treatment within 4 week study entry . Active infection , collagen vascular disease , vasculitis , glomerulonephritis , New York Heart Association class II IV heart disease and/or serious illness . Prior external beam radiation therapy maximum tolerate dose level normal organ would exceed additional irradiation . Pregnancy . Allergy iodine previous sensitization mouse protein document positive antimouse antibody ELISA test . Known brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Tositumomab and/or Iodine I 131 Tositumomab</keyword>
	<keyword>B-cell non-Hodgkin 's lymphoma</keyword>
	<keyword>Dose-limiting toxicity</keyword>
	<keyword>Bexxar</keyword>
</DOC>